-

Shareholder Alert: Robbins LLP Announces eHealth, Inc. (EHTH) Sued for Misleading Shareholders

SAN DIEGO & SANTA CLARA, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of eHealth, Inc. (NASDAQ: EHTH) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 19, 2018 and April 7, 2020. eHealth provides private health insurance exchange services to individuals, families, and small businesses in the United States and China.

If you suffered a loss as a result of eHealth's misconduct, click here.

eHealth, Inc. (EHTH) Accused of Misleading Shareholders

According to the complaint, on January 22, 2019, eHealth issued a press release announcing its full year 2018 results, touting the Company's "operational achievements" and its ability "to exceed [its] revenue and EBITDA expectations for 2018." Throughout the relevant period, eHealth continued to reaffirm the Company's strong momentum with reports of increasing enrollment and revenue growth, each time attesting that the reports fairly represented "the financial condition and results of operations of eHealth, Inc." Contrary to eHealth's representations, on April 8, 2020, Muddy Waters Research published a report disclosing "eHealth's highly aggressive accounting masks what we believe is a highly unprofitable business" and that "the key driver of growth since 2018 has been [eHealth's] reliance on Direct Response television advertising, which attracts an unprofitable, high churn enrollee." As a result of its findings, Muddy Waters concluded that "[eHealth] management is, in our view, running a massive stock promotion." On this news, eHealth's stock price fell $12.82, or 12%, to close at $103.20 per share.

eHealth, Inc. (EHTH) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:EHTH

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom